Changes in serum soluble IL-2 receptors (sIL-2R) and immunosuppressive acidic protein (IAP) associated with chemotherapy for lung cancer.

Abstract	Using sIL-2R and IAP values as indices, we examined the effect of administering BRMs to relieve bone marrow suppression and immunosuppression associated with modified VP therapy (CBDCA + VP-16) in patients with lung cancer. G-CSF significantly improved leukopenia. PSK inhibited decreases in the leukocyte count, although the action of PSK was weaker than that of G-CSF. It was shown that there was no relapse or that the course after relapse was slow, in patients showing gradual changes in sIL-2R and IAP values or showing low sIL-2R and IAP levels. Serum sIL-2R levels provide a useful indicators for continuing chemotherapy and evaluating the patient's status. In addition, evaluating a combination of sIL-2R levels and IAP levels allows the prediction of the course of the disease after relapse, and it was suggested that BRMs administration was also useful for maintaining the effects of chemotherapy.
Authors	R Katoh, S Takenoshita, Y Shimizu, S Tanaka, Y Yajima, Y Nagamachi
Journal	Anticancer research (Anticancer Res) 1997 Sep-Oct Vol. 17 Issue 5B Pg. 3787-92 ISSN: 0250-7005 [Print] Greece
PMID	9427781 (Publication Type: Journal Article)
Chemical References	Biomarkers, Tumor Immunologic Factors Neoplasm Proteins Proteoglycans Receptors, Interleukin-2 immunosuppressive acidic protein Granulocyte Colony-Stimulating Factor polysaccharide-K Etoposide Carboplatin Cisplatin
Topics	Adenocarcinoma (blood, drug therapy) Adult Aged Antineoplastic Combined Chemotherapy Protocols (adverse effects) Biomarkers, Tumor (blood) Carboplatin (administration & dosage) Carcinoma, Small Cell (blood, drug therapy) Carcinoma, Squamous Cell (blood, drug therapy) Cisplatin (administration & dosage) Etoposide (administration & dosage) Female Granulocyte Colony-Stimulating Factor (therapeutic use) Humans Immunologic Factors (therapeutic use) Lung Neoplasms (blood, drug therapy) Male Middle Aged Neoplasm Proteins (blood) Proteoglycans (therapeutic use) Receptors, Interleukin-2 (blood)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!